{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:46:52Z","timestamp":1776260812115,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG\/k monoclonal antibody that targets CD38, a glycoprotein uniformly expressed on human plasma cells. Daratumumab has been utilized in recent years with unprecedented responses in multiple myeloma. In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and improvement in organ function. Here, we report real-life treatment with Daratumumab in 33 AL amyloidosis patients treated within the Regional Tuscan Myeloma network at 5 centers with associated MGUS or SMM (n = 15) or symptomatic MM (n = 18). Patients were treated at relapsed\/refractory disease stages (n = 29) with a median of one previous line of therapy or at diagnosis (n = 4). Daratumumab showed good efficacy, representing 60% of good hematological responses and 50% of organ responses in a real-life population of patients with an acceptable toxicity profile.<\/jats:p>","DOI":"10.3390\/jpm12030484","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:30:14Z","timestamp":1647811814000},"page":"484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Daratumumab in AL Amyloidosis: A Real-Life Experience of the \u201cRTM\u201d (Regional Tuscan Myeloma Network)"],"prefix":"10.3390","volume":"12","author":[{"given":"Vincenzo","family":"Sammartano","sequence":"first","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-3516","authenticated-orcid":false,"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[{"name":"Hematology, Careggi Hospital, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ciofini","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Candi","sequence":"additional","affiliation":[{"name":"UOS Ematologia, San Donato Hospital, ASL8, 52100 Arezzo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Pengue","sequence":"additional","affiliation":[{"name":"Hematology, Careggi Hospital, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4291-8875","authenticated-orcid":false,"given":"Maria","family":"Del Giudice","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-5559","authenticated-orcid":false,"given":"Irene","family":"Attucci","sequence":"additional","affiliation":[{"name":"Hematology, Careggi Hospital, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Bacchiarri","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ubaldo","family":"Occhini","sequence":"additional","affiliation":[{"name":"UOS Ematologia, San Donato Hospital, ASL8, 52100 Arezzo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pirrotta","sequence":"additional","affiliation":[{"name":"Ematologia Clinica e Oncoematologia, Ospedale San Giuseppe, 50053 Empoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Perfetto","sequence":"additional","affiliation":[{"name":"IV Internal Medicine Division, Careggi Hospital, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-3913","authenticated-orcid":false,"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-6891","authenticated-orcid":false,"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic Amyloidosis in England: An epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","article-title":"Human CD38: A glycoprotein in search of a function","volume":"15","author":"Malavasi","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fonc.2014.00241","article-title":"Therapeutic Advancements in Multiple Myeloma","volume":"4","author":"Gozzetti","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1358\/dot.2021.57.10.3313853","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"57","author":"Goldsmith","year":"2021","journal-title":"Drugs Today"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Palladini, G., Milani, P., Malavasi, F., and Merlini, G. (2021). Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. Cells, 10.","DOI":"10.3390\/cells10030545"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: Results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ajh.25828","article-title":"High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate","volume":"95","author":"Milani","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13506129.2020.1730791","article-title":"Treatment with daratumumab in patients with relapsed\/refractory AL amyloidosis: A multicentric retrospective study and review of the literature","volume":"27","author":"Lecumberri","year":"2020","journal-title":"Amyloid"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: Prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/13506129.2020.1765768","article-title":"Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed\/refractory AL amyloidosis","volume":"27","author":"Cohen","year":"2020","journal-title":"Amyloid"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.15455","article-title":"Daratumumab proves safe and highly effective in AL amyloidosis","volume":"185","author":"Khouri","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Roccatello, D., Fenoglio, R., Naretto, C., Baldovino, S., Sciascia, S., Ferro, M., and Rossi, D. (2020). Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103232"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ejh.13535","article-title":"Daratumumab for relapsed AL amyloidosis\u2014When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review","volume":"106","author":"Shragai","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2016-06-722496","article-title":"First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/ejh.13008","article-title":"Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients","volume":"100","author":"Gran","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/1078155218815305","article-title":"Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement","volume":"25","author":"Arnall","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00277-018-3566-4","article-title":"Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage","volume":"98","author":"Canichella","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13506129.2019.1600498","article-title":"Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fc\u03b3 receptor 3A V158F polymorphisms","volume":"26","author":"Lee","year":"2019","journal-title":"Amyloid"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/13506129.2019.1615428","article-title":"Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)","volume":"26","author":"Ghilardi","year":"2019","journal-title":"Amyloid"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hon.2677","article-title":"Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden","volume":"37","author":"Schwotzer","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_36","first-page":"e24","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Carpentier","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clml.2019.10.019","article-title":"Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement","volume":"20","author":"Godara","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/bloodadvances.2019000776","article-title":"Organ responses with daratumumab therapy in previously treated AL amyloidosis","volume":"4","author":"Chung","year":"2020","journal-title":"Blood Adv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0037-1963(00)90013-1","article-title":"Fluorescence in situ hybridization: Uses and limitations","volume":"37","author":"Gozzetti","year":"2000","journal-title":"Semin Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/bloodadvances.2018021253","article-title":"When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression","volume":"3","author":"Palladini","year":"2019","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis","volume":"34","author":"Muchtar","year":"2020","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"570187","DOI":"10.3389\/fonc.2020.570187","article-title":"Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients","volume":"10","author":"Gozzetti","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jim.2016.12.006","article-title":"A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates","volume":"442","author":"Delgado","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"ref_47","first-page":"27","article-title":"Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses","volume":"76","author":"Loken","year":"2008","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14737159.2017.1332996","article-title":"Utilizing next-generation sequencing in the management of multiple myeloma","volume":"17","author":"Lionetti","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15075","article-title":"Molecular detection of minimal residual disease in multiple myeloma","volume":"181","author":"Bai","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gozzetti, A., Raspadori, D., Bacchiarri, F., Sicuranza, A., Pacelli, P., Ferrigno, I., Tocci, D., and Bocchia, M. (2020). Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. J. Pers. Med., 10.","DOI":"10.3390\/jpm10030120"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/3\/484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:37:58Z","timestamp":1760135878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/3\/484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jpm12030484"],"URL":"https:\/\/doi.org\/10.3390\/jpm12030484","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]}}}